India’s growing GLP-1 medication sector is experiencing a seismic shift as affordable generics challenge premium brands like Mounjaro and Ozempic, transforming the landscape of diabetes and obesity treatments.
India’s drug market has entered a new phase in which GLP-1 medicines, a class of diabetes treatments that also curb appetite, are no longer a niche premium category but one of the main engines of growth. Data reported by the Financial Express from Nomura showed anti-diabetes was the fastest-growing major therapy area in July, with GLP-1 products contributing about 48% of that segment’s expansion. At the same time, India Today reported that Eli Lilly’s Mounjaro had held the position of India’s top-selling drug since October last year. Yet the story is no longer simply about one runaway brand: cheaper semaglutide rivals are rapidly redrawing the competitive map.
That shift is striking partly because of how quickly Mounjaro rose. Business Standard reported in April that the tirzepatide brand had already become India’s highest-selling drug by value in the 2025-26 financial year, generating Rs 923 crore within a year of its March 2025 launch. It overtook long-established mass-market names including GSK’s Augmentin, on Rs 916 crore, and USV’s Glycomet, on Rs 898 crore. The feat was especially notable because Mounjaro sells at a premium few Indian drugs can match: Business Standard put the monthly cost at Rs 14,000 for the 2.5 mg dose and Rs 17,500 for the 5 mg dose, compared with roughly Rs 117 for a strip of Augmentin 625 and Rs 113 for Glycomet GP.
The balance began to change when semaglutide lost patent protection in India on 20 March. Business Standard said more than 23 versions entered the market within days, while India Today reported that 31 companies moved into the generic semaglutide opportunity. March data cited by both Business Standard and the Economic Times showed semaglutide sales climbing to Rs 59 crore from Rs 48 crore in February, lifting its share of the GLP-1 market to 33% from 25%. Tirzepatide still led, but its March sales slipped 15% to Rs 114 crore from Rs 135 crore, and Eli Lilly’s value share fell to 56% from 61%. According to the Economic Times, Torrent alone captured 3% of the Rs 1,600-crore GLP-1 agonist market within the first 10 days of launch.
Price was at the centre of that change. The Economic Times quoted Sheetal Sapale of PharmaTrac as saying: “Even as Mounjaro dominates the GLP-1 segment…launch of branded generics has made the semaglutide molecule stronger.” She added: “Both generics and innovator semaglutide are far more economical than tirzepatide.” The same report said Ozempic and Wegovy started at Rs 5,660 a month, while generic semaglutide was available from around Rs 1,300 for vials and Rs 1,800 for injectable pens. That publication separately cited Mounjaro’s base monthly cost at Rs 13,000, a slightly lower figure than the pricing given by Business Standard. Vishal Manchanda of Systematix Group told the Economic Times that within 12 to 14 months “Probably 80% of the weight loss people will be on semaglutide, 20% will be on Mounjaro”. Lilly pushed back. Winselow Tucker, the company’s India head, said tirzepatide’s “unique mechanism of action and strong clinical evidence clearly distinguish it in a crowded market”.
Even so, the market did not rise in a straight line. India Today said the anti-obesity drug market had reached Rs 1,906 crore on a moving annual basis by May 2026, with tirzepatide accounting for Rs 1,207 crore and semaglutide Rs 589 crore. But it also reported that government caution and tighter patient selection were steering the category towards more disciplined, prescription-led growth. The Financial Express then recorded the first monthly setback in June: GLP-1 sales dipped to Rs 227 crore from Rs 236 crore in May. Tirzepatide eased to Rs 130 crore from Rs 136 crore, while semaglutide slipped to Rs 91 crore from Rs 93 crore. The paper said the early generic rush had started to plateau, shifting attention towards physician adoption, long-term adherence and the size of the eligible patient pool.
That pause proved brief. BioSpectrum India, citing Pharmarack Technologies, reported that the GLP-1 agonist market rebounded in July and reached Rs 2,215 crore in moving annual turnover, up 235%, with a five-year compound annual growth rate of 98%. The market was nearly five times larger than it had been in January 2025. Tirzepatide remained the biggest growth driver, reaching Rs 1,398 crore in July MAT, while semaglutide rose to Rs 717 crore, up 70% from Rs 421 crore a year earlier. Older GLP-1 therapies were losing ground: dulaglutide fell 21% to Rs 64 crore and liraglutide was almost flat at Rs 34 crore.
The July figures also showed how competition is concentrating rather than fragmenting. BioSpectrum India said 11 of the 33 generic semaglutide injectable brands accounted for 80% of generic unit sales in July. At the same time, the original brands continued to gain ground. Wegovy’s unit sales rose from 13.9 thousand in May to 15.7 thousand in July, while Ozempic increased from 15.6 thousand to 19.7 thousand. Poviztra and Extensior each reached 2.6 thousand units in July. The Financial Express had already noted in June that generics made up 82% of semaglutide unit sales, even as the four innovator brands continued to grow steadily, suggesting that lower prices alone are not deciding the market.
The wider pharmaceutical backdrop helps explain why this matters beyond obesity drugs. According to Nomura figures reported by the Financial Express, India’s pharmaceutical market grew 12.1% year on year in July, helped by price rises, new launches and a recovery in patient volumes. Price increases contributed about 6 percentage points of that growth, new launches 3.7 and volumes 2.3. Zydus Lifesciences and Sun Pharmaceutical led the pack among the companies it tracks, with growth of 20.8% and 17.8% respectively, while Cipla, Torrent Pharma and Lupin also posted strong gains. In other words, GLP-1 is not an isolated fad inside Indian pharma; it is becoming one of the clearest tests of how drugmakers balance innovation, affordability and scale. Mounjaro’s rise has shown how quickly a premium therapy can break into the mainstream. The flood of semaglutide copies has shown how quickly that lead can come under pressure.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
